Lenis Group is pleased to announce the appointment of Richard Jones as Chief Executive Officer, as the business enters its next phase following investment from Great Point Partners.
Richard joins Lenis with extensive experience across the pharmaceutical and healthcare sectors. He has held senior leadership roles spanning commercial strategy, market access and distribution, leading international teams working with pharmaceutical and biotech organisations on evidence development and access.
Across his career, Richard has operated in complex regulated markets, helping organisations grow and improving how therapies are brought to market.
His appointment comes at a point of momentum for Lenis, as the organisation continues to build its position as a full-service partner of choice in specialty pharmaceutical commercialisation and distribution in the CEE region.
Richard said: “What stood out to me about Lenis was the strength of the team and its unwavering focus on quality which, through Vita Godec’s inspiring passion, has created a culture of can-do advocates. That consistency, carried by the wider team, has been central to building a trusted and respected partner in the market. My focus is to build on that foundation, evolving the offering and continuing to position Lenis as the first choice for partners as market demands become more complex.”
“I’m delighted to welcome Richard to Lenis. He brings the right experience for where we are today and a clear understanding of what it takes to grow in this market. This next phase builds on the vision we set early on, supported by a team that has established a strong reputation through its focus on quality and delivery,” said Branko Huč, Founder of Lenis Group.
“Lenis operates in a part of the market where expertise and execution matter. Richard’s experience aligns with that and we see this as an important step as the business continues to grow,” said David Slattery, Principal at Great Point Partners.
As Chief Executive Officer, Richard will lead Lenis through its next stage of development, with a focus on evolving its proposition and deepening relationships across the pharmaceutical landscape.
About Lenis Group
Lenis Group is a full-service commercialisation partner for niche and specialty prescription medicines, recognised as a key access enabler across the CEE region. By combining market access, regulatory, medical, marketing, quality, pharmacovigilance and GMP/GDP-compliant distribution capabilities, Lenis simplifies entry into this fragmented region and offers turnkey (“one stop shop”) solutions to its pharma partners. With a strong track record in launches of innovative medicines, Lenis also manages early access programs, unlicensed medicine supply and drug-shortage mitigation, with a focus on infectology, oncology, neurology, rare diseases and other high-impact specialties. In close collaboration with hospitals, NGOs and patient organizations, Lenis designs pragmatic access pathways that address local reimbursement, regulatory and logistical barriers, helping to improve treatment outcomes and standard of care for vulnerable patient populations across the CEE and Adriatic markets.
About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.7B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.
